Parkinson’s Disease Treatment Market

Global Parkinson’s Disease Treatment Market Size (2024 to 2032)

The size of the global parkinson’s disease treatment market was worth USD 5.06 billion in 2023. The global market is anticipated to grow at a CAGR of 5.97% from 2024 to 2032 and be worth USD 8.53 billion by 2032 from USD 5.36 billion in 2024. 

Current Scenario of the Global Parkinson’s Disease Treatment Market

The slow development in stages of a neurological disorder that has features of the inexpressive face, the slowdown of spontaneous moments, walking with short steps, particular posture and muscle weakness which is caused by an area in the brain, and also low production of the neurotransmitter dopamine, is often termed as Parkinson's disease.

MARKET DRIVERS

The growing aging population worldwide suffering from Parkinson's disease is the primary factor driving the global Parkinson’s disease treatment market growth.

Additionally, the increase in healthcare expenditure by the governments in research and development is the factor that drives the growth of the Parkinson's disease treatment market. The pharmacies that are available online are to grow faster during the forecast period. Robust health infrastructure and skilled neurologist professionals are the hospitals' driving factors, which propel the global Parkinson's disease treatment market. Government authority or license, especially having the power to remove others from applying branded drugs and the strong pipeline of products, is the opportunity provided during the forecast period.

MARKET RESTRAINTS

Understanding what causes the complexity and diversity of Parkinson's disease is the main challenge for investigators or researchers. Investigators often work with local communities and caregivers to identify the problems of living with Parkinson's disease to translate scientific discoveries into patient care. The booklet named "Parkinson's Disease 2014: Advancing Research, Improving Lives" highlights the recent progress made in Parkinson's disease research and maps out the challenges and priorities. As the symptoms of PD progress, like walking, talking, swallowing, and completing other tasks, which can become challenging. Healthcare providers, individuals with Parkinson's disease, caretakers, and other stakeholders together to assist the state of Parkinson's disease, define the key or main challenges, and set priorities for advancing Parkinson's Disease research. It can be challenging to consent from the prodromal and early stage of Parkinson's patients to give CSF samples for biomarker assessments in clinical trials.

REPORT COVERAGE

SEGMENTAL ANALSIS

Globlal Parkinson’s Disease Treatment Market Analysis By Drug Class

Based on the drug class analysis, the carbidopa segment accounted for the largest share of the market in 2023, and the segmental growth is majorly driven by the strength of the drug. The increasing aging population and regular increase of Parkinson’s diseases are considered to boost the market growth during the forecast period.

Globlal Parkinson’s Disease Treatment Market Analysis  By Distribution Channel

Based on the distribution channel, the hospital pharmacies segment held the leading share of the global market in 2023. The growing number of patients visiting hospitals due to the availability of diagnostic laboratories and the existence of expert neurologists are propelling the market growth during the analysis period.

Globlal Parkinson’s Disease Treatment Market Analysis  By Patient Care Setting

Based on the Patient Care Settings analysis, the hospital segment is anticipated to account for the largest share of the market during the forecast period owing to factors such as the robust healthcare infrastructure, reducing the need to visit pharmacies, and increasing hospital settings.

Clinics hold a small share of the market due to the scarcity of neurologists, where most patients prefer hospitals.

REGIONAL ANALYSIS

Geographically, Europe was the leading market for Parkinson’s Disease Treatment in 2023, followed by North America and the Asia Pacific regions. The presence of established key players in this region, growing spending on healthcare, the expected growth of Parkinson’s diseases in the region, and gene therapy has also increased.

North America is next to Europe to dominate the global Parkinson's disease treatment market due to reimbursement policies and regular increase of diseases, increasing expenditure on research and development activities, and regular FDA acceptances for novel pipeline drugs. The U.S. is projected to have the largest share in the market. Rise in older people population and availability of reimbursement policies and increasing consciousness among the population. Canada is behind the U.S. in leading the market due to recent product launches and many therapies among the product pipelines.

Due to the vast population base in the region, the Asia Pacific region is expected to have the fastest growth rate during the forecast period. The factors like developing several headache cases, rising public awareness regarding the diseases, enhanced distribution networks in pharma emerging nations, and massive demand for disease treatment in countries like China and Japan.

Latin America is expected to have steady and fixed growth in Parkinson’s treatment market during the estimated period. The market growth is attributed to supportive government policies, high sales in generic medicines, and a growing number of generic drug manufacturers.

The Middle East & Africa is expected to have limited growth in the market due to strength and extensive assumption in treating Parkinson’s disease treatment fueling the market growth.

KEY PLAYERS IN THE PARKINSON’S DISEASE TREATMENT MARKET

Some of the notable market participants leading the global Parkinson's disease treatment market profiled in this report are Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).

RECENT MARKET HAPPENINGS

• In February 2020, Sun Pharma launched severe nodular acne management capsules in the US. It is launched for patients who are below 12 years of age and older. It can be taken with or without food.

• In June 2019, Wockhardt got a booster from USFDA. The company has said that it has received a zero issue after inspecting bioequivalence from the US health regulator.

• In October 2019, Sun Pharma launched Cequa to treat dry eye disease in the US. The company launched an ophthalmic solution called Cequa, used to treat dry eyes in the US market. 
• In February 2020, Sun Pharma proposed to set up a production unit in Pharma City. The founder and managing director Dilip Shanghvi of Sun Pharma told Times Of India that they would manufacture Hyderabad's production company.

DETAILED SEGMENTATION OF THE GLOBAL PARKINSON’S DISEASE TREATMENT MARKET INCLUDED IN THIS REPORT

This research report on the global Parkinson's disease treatment market has been segmented and sub-segmented into the following categories.

By Drug Class

• Dopamine Receptor Antagonists   

  • Pramipexole

  • Ropinirole
  • Apomorphine
  • Rotigotine
• Mono Amine Oxidase Inhibitors    
  • Selegiline
  • Rasagiline
• Carbidopa
• Anticholinergics   
• Other Drug Classes 

By Distribution Channel

• Retailer Pharmacies
• Hospital Pharmacies
• Online Pharmacies 

By Patient Care Setting

• Clinics       
• Hospitals  

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa